Indivi
Indivi develops functional biomarkers that measure key disability concepts of importance for drug development trials in neuroscience
About Indivi
Indivi is a TechBio company developing functional biomarkers as drug development tools for neurological diseases in the form of sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision and voice. Indivi is committed to developing future-proof and transformative digital endpoints as deep phenotyping instruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias. Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in data science, clinical development, signal processing engineering, and advanced analytics including computational intelligence. Through end-to-end joint endeavors with biopharmaceutical companies, Indivi is poised to continue its growth in the nascent digital endpoint industry to improve the probability of technical and regulatory success in neuroscience drug development.
Company Facts
- Headquarters
- Basel
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00051_00100
- Total Funding
- $22,995,577
- Last Funding Type
- series_unknown
- Last Funding Date
- 2025-11-12
- Website
- indivi.io
Industries & Categories
Clinical Trials, Medical Device, Neuroscience
Social Links
Canonical: https://fsome.com/organization/indivi-112197 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.